CD8A and Splenomegaly: Overall, these data demonstrate that treating aged mice with rIL‐37 abrogates aging‐associated splenomegaly and restores the representation of CD4+ and CD8+ T‐cells to youthful levels (Figure 1d), whereas treating young mice with this anti‐inflammatory cytokine does not impact the distribution of splenic‐derived T‐cells.